Desvenlafaxine 50mg ER Tablets

Desvenlafaxine 50mg ER Tablets are a serotonin and noradrenaline reuptake inhibitor used for major depressive disorder. The extended-release formulation provides prolonged medicine delivery for regular daily treatment. It is not an immediate-relief medicine for an isolated anxious episode.
Swallow the extended-release tablet whole with water once daily, with or without food, at a consistent time. Do not divide, crush, chew or dissolve it.
Desvenlafaxine inhibits reuptake of serotonin and noradrenaline, increasing their availability in nerve circuits involved in mood regulation. Extended release changes delivery of the dose, not the active ingredient's mechanism.
Nausea, constipation, sweating, insomnia, dizziness and sexual difficulties can occur. Suicidal thoughts, seizures, severe confusion or agitation with fever and muscle stiffness require urgent attention.
Check blood pressure before treatment and during use. Tell your doctor about kidney impairment, bipolar disorder, glaucoma, low sodium, bleeding problems, pregnancy and breastfeeding. MAO inhibitors, tramadol and other serotonergic medicines can cause serious interactions. Sudden withdrawal may cause dizziness, sensory disturbances, nausea or marked mood changes.
A useful response can improve persistent sadness, loss of interest and reduced everyday functioning. Benefit develops over weeks; increasing the dose does not guarantee a better response and can increase adverse effects.
Some extended-release tablets leave an empty shell after the medicine has been released. This does not, by itself, mean the dose was not absorbed.
The full benefit can take several weeks. Follow-up considers mood and daily functioning as well as early adverse effects, rather than judging treatment from the first few days.
No. Desvenlafaxine is an active metabolite of venlafaxine, but the products have different dosing and pharmacokinetic considerations. They are not exchanged milligram for milligram.
No. Splitting can disrupt the extended-release system. A taper needs a suitable lower-strength presentation or another planned regimen.
SNRI: a serotonin and noradrenaline reuptake inhibitor. Extended release: medicine delivery spread over time. Active metabolite: a substance formed from a medicine that also has pharmacological activity. Discontinuation symptoms: effects caused by reducing or stopping treatment too quickly; AR: Desvenlafaxine 50mg أقراص ممتدة التحرر; FR: Desvenlafaxine 50mg comprimés à libération prolongée; PT: Desvenlafaxine 50mg comprimidos de libertação prolongada; ES: Desvenlafaxine 50mg comprimidos de liberación prolongada; RU: Desvenlafaxine 50mg таблетки пролонгированного высвобождения; ID: Desvenlafaxine 50mg tablet lepas lambat; VI: Desvenlafaxine 50mg viên nén giải phóng kéo dài; MS: Desvenlafaxine 50mg tablet pelepasan berpanjangan; TL: Desvenlafaxine 50mg tabletang may pinalawig na paglabas; ZH-SG: Desvenlafaxine 50mg 缓释片
International B2B Enquiry
Send a structured B2B enquiry for Desvenlafaxine 50mg ER Tablets under Mental Health. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Desvenlafaxine 50mg ER Tablets